ArticleFrontiers in oncology2025
The value of intratumoral and peritumoral radiomics features based on multiparametric MRI for predicting molecular staging of breast cancer.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Development and external validation of a machine learning-based multimodal radiomics nomogram for predicting progression-free survival in triple-negative breast cancer.Translational cancer research · 2026Article
- Radiomic features from intratumoral and peritumoral regions on portal venous phase CT for multicenter prediction of TP53 mutation in pancreatic cancer.Frontiers in oncology · 2026Article
- Segmentation variability and radiomics stability for predicting triple-negative breast cancer subtype using magnetic resonance imaging.Journal of medical imaging (Bellingham, Wash.) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: A model for preoperative prediction of molecular subtypes of breast cancer using tumor and peritumor radiomics features from multiple magnetic resonance imaging (mMRI) sequences, combined with semantic features. Materials and methods: A total of 254 female patients with pathogically confirmed breast cancer were enrolled in this study. Preoperative mMRI, including T2-weighted imaging (T2WI), diffusion-weighted imaging (DWI), and dynamic contrast-enhanced MRI (DCE) sequences, covered the entire breast. To analyze the MRI semantic features of different molecular subtypes of breast cancer and identify independent predictive risk factors. Thirty-three binary classification models were established based on the radiomic features of different sequences and peritumoral ranges. The best radiomics model was selected by comparing the performance of the above radiomics models. At the same time, the best sequence and peritumoral extent were extracted from the target features, the radiomics score was calculated, and independent risk factors were predicted. Finally, a nomogram was established for preoperative prediction of Triple-Negative Breast Cancer (TNBC), Hormone Receptor (HR) positive and HER2 negative (HR+/HER2-), and HER2+ molecular staging types of breast cancer. Results: Tumor length, edge enhancement, and peritumoral edema were independent risk factors for predicting the different molecular types of breast cancer. The best MRI sequence was DCE and the best peritumoral margin was 6 mm. The AUC of the nomogram based on the optimal sequence(DCE) and optimal peritumoral range (6 mm) combined with independent risk factors were 0.910, 0.909, and 0.845, respectively. Conclusion: The nomogram based on independent predictors combined with intratumoral and peritumoral radiomics scores can be used as an auxiliary diagnostic tool for molecular subtype prediction in breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.